Antibacterial agents reducing the risk of resistance development

The most important goal of medical microbiology in terms of treating infectious diseases nowadays and in the coming decades will be the development of antibacterial agents that are effective against resistant pathogens and reduce the selection of antimicrobial resistance. In this regard, along with the search for new classic antibiotics, it is necessary to develop alternative strategies. Virulence factors that determine the key stages of the infection process, both acute and chronic, including adhesins, toxins, bacterial quorum sensing, secretory systems, could be potential targets. The strategy for the development of antivirulence drugs is already showing its potential in the treatment of nosocomial, complicated and chronic infections as part of complex therapy and for prevention. The review presents the results of studies of drugs that have already shown efficacy in model infections in animals or have either passed to the stage of clinical trials or have already been registered. The development of effective combination therapy regimens will minimize the risks of acquiring resistance.